Menú Menú

Publicaciones Científicas


Eribulin activity in soft tissue sarcoma

Dr. Ortiz Cruz,  coautor del artículo: Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral efect?

Javier Escudero, Victoria Heredia‑Soto, Yinyin Wang, Patricia Ruiz, Yingying Hu, Jose Juan Pozo‑Kreilinger, Virginia Martinez‑Marin, Alberto Berjon, Alejandro Gallego, Eduardo Ortiz‑Cruz,
Jaime Feliu, Jing Tang, Andres Redondo, Marta Mendiola and Daniel Bernabeu.

Background: Eribulin has shown antitumour activity in some soft tissue sarcomas (STSs), but it has only been
approved for advanced liposarcoma (LPS).

Methods: In this study, we evaluated the efect of eribulin on proliferation, migration and invasion capabilities in
LPS, leiomyosarcoma (LMS) and ibrosarcoma (FS) models, using both monolayer (2D) and three‑dimensional (3D)
spheroid cell cultures. Additionally, we explored combinations of eribulin with other drugs commonly used in the
treatment of STS with the aim of increasing its antitumour activity.

Results: Eribulin showed activity inhibiting proliferation, 2D and 3D migration and invasion in most of the cell line
models. Furthermore, we provide data that suggest, for the irst time, a synergistic efect with ifosfamide in all models,
and with pazopanib in LMS as well as in myxoid and pleomorphic LPS.

Conclusions: Our results support the efect of eribulin on LPS, LMS and FS cell line models. The combination of
eribulin with ifosfamide or pazopanib has shown in vitro synergy, which warrants further clinical research.
Keywords: Eribulin, Sarcoma, Proliferation, Migration, Invasion, 2D and 3D models